[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
High Risk Prostate Carcinoma
Interventions
DRUG

[F-18]Florastamin

A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).

Trial Locations (6)

Unknown

National Cancer Center, Gyeonggi-do

Korea University Anam Hospital, Seoul

Samsung Medical Center, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Ewha womans university mokdong medical center, Soeul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

FutureChem

INDUSTRY